By Fineline Cube BeOne Medicines Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), formerly BeiGene, announced that China’s National Medical Products Administration (NMPA) has granted conditional marketing approval for Imdelltra™ (tarlatamab), a DLL3-targeting bispecific T-cell engager (BiTE®) therapy developed in partnership with Amgen Inc. (NASDAQ: AMGN). The indication covers adult patients with extensive-stage small cell lung cancer (ES-SCLC) who have progressed after at least two prior systemic therapies, including platinum-based chemotherapy.
Regulatory Milestone Summary
| Parameter | Detail |
|---|---|
| Drug Name | Imdelltra (tarlatamab) |
| Class | Bispecific T-cell Engager (BiTE®) |
| Target | DLL3 (tumor) × CD3 (T cell) |
| Indication | Third-line+ ES-SCLC |
| Approval Authority | NMPA (China) |
| Approval Type | Conditional (subject to confirmatory data) |
| Commercial Lead | BeOne Medicines (mainland China) |
This approval enables immediate patient access under China’s accelerated pathway for breakthrough oncology therapies addressing critical unmet needs.
Clinical & Market Context
- Disease Burden: ES-SCLC is an aggressive neuroendocrine malignancy with limited treatment options beyond second-line; median survival in refractory settings is typically <6 months
- DLL3 Rationale: Expressed in >85% of SCLC tumors but absent in most healthy tissues, making it an ideal target for T-cell redirection
- Global Foundation: Approval supported by Amgen’s international Phase II DeLLphi-301 trial, which showed objective response rates exceeding 40% and durable disease control in heavily pretreated patients
- Safety Profile: Manageable cytokine release syndrome (mostly Grade 1–2) with established mitigation protocols
Strategic Partnership Dynamics
The approval validates the 2019 global collaboration between BeOne and Amgen, under which BeOne holds exclusive rights to develop, file, and commercialize Imdelltra in mainland China. BeOne will deploy its nationwide oncology infrastructure—spanning over 1,800 hospitals—to drive rapid market access and physician adoption.
- Reimbursement Strategy: Expected submission to National Reimbursement Drug List (NRDL) negotiations in 2026
- Competitive Edge: First-in-class DLL3-targeted therapy in China; no approved BiTEs for solid tumors previously
- Pipeline Leverage: Success strengthens joint development framework for additional Amgen assets in BeOne’s portfolio
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory status, commercial rollout, and clinical outcomes. Actual results may differ due to post-marketing requirements, competitive dynamics, and real-world adoption patterns.